Gene therapy injection aims to restore sight in rare blindness

NCT ID NCT06952842

Recruiting now Disease control Sponsor: Chigenovo Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. The therapy is injected into the eye and uses a harmless virus to deliver a gene-editing tool. The trial includes 18 adults and will check safety and whether it improves vision over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZVS203e (a gene therapy using a harmless virus to deliver a gene-editing tool into the eye)
What this could lead to: If successful, this could slow or partially reverse vision loss in people with a specific genetic form of retinitis pigmentosa.
What could go wrong: This is an early-phase trial with only 18 participants, so results may not apply to everyone. Gene therapies can cause inflammation or other side effects, and vision improvement may be limited or temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinitis pigmentosa retinitis pigmentosa 4

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINITIS PIGMENTOSA

Contacts and locations

Locations

Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, 100191, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.